November 21st 2023
Those receiving dostarlimab experienced numerical improvements from baseline in terms of quality of life, emotional functioning, pain, and back and pelvis pain scores.
October 27th 2023
The median progression-free survival was not reached with atezolizumab plus chemotherapy vs 6.9 months in the placebo group of patients with advanced or recurrent endometrial cancer.
October 22nd 2023
Durvalumab plus first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib, emerges as a potentially effective combination for patients with limited treatment options.
July 31st 2023
The FDA has approved dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, as determined by an FDA-approved test, or microsatellite instability-high.
July 28th 2023
Patients with TP53 wild-type endometrial cancer experienced a median progression-free survival of 27.4 months vs 5.2 months with placebo.
Dostarlimab Maintains HRQOL in 3-Year Follow-Up Of Patients With Early Endometrial Cancer
An analysis of patient-reported outcomes in the phase 3 RUBY trial supports dostarlimab use in patients with primary advanced or recurrent endometrial cancer.
Pembrolizumab Plus Lenvatinib Gains NICE Recommendation for Previously Treated Advanced or Recurrent Endometrial Cancer
The United Kingdom’s National Institute for Health and Care Excellence has updated their guidelines to recommend pembrolizumab plus lenvatinib for patients with previously treated endometrial cancer.
Adding Pembrolizumab to SOC Reduces Risk of Disease Progression or Death in dMMR/pMMR Advanced Endometrial Cancer
Pembrolizumab inspired a 70% risk reduction in women with mismatch repair–deficient advanced endometrial cancer and a 46% risk reduction in patients with mismatch repair–proficient disease.
Updated PFS Readouts From RUBY Trial Support Dostarlimab Use in Recurrent Endometrial Cancer
Dostarlimab met its primary end point in the phase 3 RUBY trial by increasing the 2-year progression-free survival rate to 36.1%, compared with 18.1% with placebo.
Second-Line Options Expand With the Use of Immunotherapy in Advanced Endometrial Cancer
Oncology nurse experts review their experiences with newcomers for the treatment of advanced endometrial cancer and exchange best practices in caring for this population.
Lenvatinib Plus Pembrolizumab Elicits Durable Responses in Patients With Endometrial Cancer
In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.
GCLQ and LELSQ Show Concordance in Assessment of Lymphedema in Patients With Endometrial Cancer
The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer.
Arn Unpacks Dostarlimab Approval for Patients With dMMR Advanced Endometrial Cancer
Courtney R. Arn, APRN-CNP, discusses the recent approval of dostarlimab for patients with mismatch repair–deficient recurrent or advanced endometrial cancer.
Lenvatinib/Pembrolizumab Efficacy Data Holds Up in Updated KEYNOTE-146 Analysis for Advanced Endometrial Carcinoma
Updated findings from the KEYNOTE-146 trial support the use of lenvatinib/pembrolizumab in advanced endometrial cancer.
FDA Grants Regular Approval to Dostarlimab for dMMR Endometrial Cancer
Dostarlimab-gxly has been granted regular approval for the treatment of patients with dMMR endometrial cancer. The label comes with warnings for immune-mediated adverse effects.
First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery
Kathleen Lutz, RN, NP-BC WH, explains the most commonly used first-line treatment options in patients with advanced endometrial cancer who are unsuitable candidates for surgery.
Currently Available Treatment Modalities in Endometrial Cancer
The panel reviews the current treatment modalities for endometrial cancer and in what circumstances each is considered for a patient.
Oncology Drug Crash Course: Lenvatinib (Lenvima) for Advanced Endometrial Cancer
Lenvatinib is approved in combination with pembrolizumab for the treatment of patients with advanced endometrial cancer who have disease progression after systemic therapy, are not candidates for curative surgery or radiation, and who are mismatch repair proficient or not microsatellite instability–high.
Dostarlimab Improves Progression-Free Survival in Advanced or Recurrent Endometrial Cancer
Dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab alone, met a predetermined progression-free survival end point in the phase 3 RUBY trial.
Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer
The panel shares how they determine a treatment regimen for patients with advanced endometrial cancer taking into consideration fertility and family planning, hereditary conditions, and comorbidities.
Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer
Kathleen Lutz, RN, NP-BC WH, presents a 76-year-old woman with advanced endometrial cancer, and the panel assesses the chosen treatment regimens.
Resources for Patients With Endometrial Cancer
Certified Nurse Practitioner Kimberly Spickes shares the educational and supportive resources she recommends for patients with newly-diagnosed advanced endometrial cancer.
Conversations with Patients With Advanced Endometrial Cancer Before and After Diagnosis
Nurse Practitioners Kathleen Lutz and Kimberly Halla describe the conversations they have with patients with advanced endometrial cancer before and after diagnosis and the common questions they hear.
Initial Consultation of Patients With Advanced Endometrial Cancer
Kimberly Halla, NP, explains the staging of endometrial cancer and the standards for biomarker testing at her institution.
Symptoms and Diagnosis of Endometrial Cancer
Kimberly A. Spickes, CNP, gives an overview of the typical symptoms women with endometrial cancer present with, discusses how these symptoms are similar and different from those seen with other gynecologic malignancies, and reviews risk factors for endometrial cancer.
Letrozole Plus Abemaciclib Draw Clinical Activity in ER+ Endometrial Cancer
A combination of the aromatase inhibitor letrozole and the CDK4/6 inhibitor abemaciclib may help patients with recurrent estrogen receptor–positive endometrial cancer achieve responses.
Intense-Modulated Radiation Therapy Reduces Chronic Diarrhea and Urinary Toxicity in Women With Cervical or Endometrial Cancer
Intense-modulated therapy was associated with less patient-reported toxicities than conventional radiotherapy and demonstrated a comparable efficacy profile.
Nurse Takeaways: Latest Pembrolizumab Indication in Endometrial Cancer
Courtney Arn, APRN-CNP, a nurse practitioner comments on the recent approval of pembrolizumab for patients with MSI-H/dMMR advanced endometrial carcinoma.
FDA Follow-Up: Utilizing Pembrolizumab for MSI-H/dMMR Advanced Endometrial Carcinoma
Courtney Arn, APRN-CNP, a nurse practitioner who supported cohorts D and K of the KEYNOTE-158 study, discusses the recent approval of pembrolizumab for patients with MSI-H/dMMR advanced endometrial carcinoma.
Maintenance Selinexor Yields Survival Benefit in Advanced or Recurrent Endometrial Cancer
Selinexor demonstrated impressive efficacy in extending progression-free survival among patient with advanced or recurrent endometrial cancer, particularly among patients with wild-type p53 endometrial cancer.
Selinexor Improves Progression-Free Survival in Advanced Endometrial Cancer
Selinexor, an oral selective inhibitor of nuclear export, demonstrated promising efficacy in increasing progression-free survival among women with advanced endometrial cancer.
Potentially Game-Changing Clinical Trials in Endometrial Cancer Seek to Evaluate Immunotherapeutic Approaches
An expert from the University of Colorado (UC Health) comments on ongoing clinical trials which promise to shake up the treatment paradigm of endometrial cancer.
More Research Is Needed to Utilize Biomarkers in Endometrial Cancer
An expert from the Ohio State University Comprehensive Cancer Center discusses whether predictive biomarkers hold the potential to change endometrial prognoses.
Lenvatinib/Pembrolizumab Combo Continues to Show Benefit in Advanced Endometrial Cancer
A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.
Checkpoint Blockade Drives Progress in Endometrial Cancer Treatment
An expert from NYU Langone outlines how checkpoint blockade approvals have helped advance endometrial cancer management.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512